HF
KIN

Halpern Financial’s Kindred Biosciences, Inc. KIN Stock Holding History

Halpern Financial’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-500
Closed -$4.24K – 196
2019
Q4 		$4.24K Buy
+500
New +$3.9K ﹤0.01% 160

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Halpern Financial's KIN Position: Q1 2020 in Review

Halpern Financial sold out of Kindred Biosciences, Inc. (KIN) in Q1 2020, closing a stake of 500 shares — an estimated $4.24K sold.

Halpern Financial first reported a position in KIN in Q4 2019 and held it in 1 quarter. The position peaked at $4.24K in Q4 2019. 77 funds tracked by Wall St. Rank hold KIN as of Q1 2020.

  • Halpern Financial reported no remaining Kindred Biosciences, Inc. position as of Q1 2020 after selling out during the quarter.
  • Halpern Financial sold 500 Kindred Biosciences, Inc. shares in Q1 2020, an estimated $4.24K.
  • Halpern Financial first reported a position in Kindred Biosciences, Inc. in Q4 2019 and held it in 1 quarter.
  • Halpern Financial's Kindred Biosciences, Inc. position peaked at $4.24K in Q4 2019.
  • 77 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q1 2020.

Based on Halpern Financial's 13F filing for Q1 2020, filed 21 Sep 2023.